Latha Vairavan - 06 May 2025 Form 3 Insider Report for Arcutis Biotherapeutics, Inc. (ARQT)

Role: SVP Chief Financial Officer
Signature: /s/ Masaru Matsuda, Attorney-in-Fact for Latha Vairavan
Issuer symbol: ARQT
Transactions as of: 06 May 2025
Transactions value $: $0
Form type: 3
Filing time: 07 May 2025, 19:27:44 UTC
Next filing: 05 Aug 2025
SEC: View on sec.gov

Reporting Owners (1)

Name	Relationship	Address	Signature	Signature date	CIK
Vairavan Latha	SVP Chief Financial Officer	C/O ARCUTIS BIOTHERAPEUTICS, INC., 3027 TOWNSGATE ROAD, SUITE 300, WESTLAKE VILLAGE	/s/ Masaru Matsuda, Attorney-in-Fact for Latha Vairavan	07 May 2025	0002065881

Transactions Table

Type	Sym	Class	Transaction	Value $	Shares	Change %	* Price $	Shares After	Date	Ownership	Footnotes
holding	ARQT	Common Stock						45.1K	06 May 2025	Direct	F1

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type	Sym	Class	Transaction	Value $	Shares	Change %	* Price $	Shares After	Date	Underlying Class	Amount	Exercise Price	Ownership	Footnotes
holding	ARQT	Stock Option (right to buy)							06 May 2025	Common Stock	5.5K	$17.67	Direct	F2
holding	ARQT	Stock Option (right to buy)							06 May 2025	Common Stock	5K	$15.82	Direct	F3
holding	ARQT	Stock Option (right to buy)							06 May 2025	Common Stock	43.5K	$3.64	Direct	F4
holding	ARQT	Stock Option (right to buy)							06 May 2025	Common Stock	23.8K	$13.69	Direct	F5

* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id	Content
F1	Represents 2,225 Restricted Stock Units ("RSUs") granted on March 3, 2022 that vest on March 1, 2026; 4,050 RSUs granted on March 2, 2023 that vest as to 1/2 each on March 1, 2026 and 2027; 8,625 RSUs granted on January 12, 2024 that vest as to 1/3 each on February 1, 2026, 2027, and 2028; 713 RSUs granted on February 13, 2024 pursuant to option exchange program that vest as to 1/3 on each of August 1, 2025, November 1, 2025, and February 1, 2026; and 11,250 RSUs granted on February 28, 2025 that vest as to 1/4 each on March 1, 2026, 2027, 2028 and, 2029, in each case subject to the Reporting Person's continuous provision of services to the Issuer through each vesting date.
F2	The option became exercisable as to 4,354 shares as of May 1, 2025. The remaining 1,146 of the 5,500 shares granted become exercisable in equal monthly installments on the first of every month, ending on March 1, 2026, in each case subject to the Reporting Person's continuous provision of services to the Issuer through each vesting date.
F3	The option became exercisable as to 2,708 shares as of May 1, 2025. The remaining 2,292of the 5,000 shares granted become exercisable in equal monthly installments on the first of every month, ending on March 1, 2027, in each case subject to the Reporting Person's continuous provision of services to the Issuer through each vesting date.
F4	The option became exercisable as to 13,594 shares as of April 12, 2025. The remaining 29,906 of the 43,500 shares granted become exercisable in equal monthly installments on the 12th of every month, ending on January 12, 2028, in each case subject to the Reporting Person's continuous provision of services to the Issuer through each vesting date.
F5	The option became exercisable as to 990 shares as of May 1, 2025. The remaining 22,760 of the 23,750 shares granted become exercisable in equal monthly installments on the first of every month, ending on March 1, 2029, in each case subject to the Reporting Person's continuous provision of services to the Issuer through each vesting date.